A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia

Leukemia

Volumn 12, Issue 6, 1998, Pages 865-868

  Weiss, M A ^a,b   Drullinsky, P ^a   Maslak, P ^a   Scheinberg, D ^a   Golde, D W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytarabine; Idarubicin; Relapsed refractory adult ALL

Indexed keywords

CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLEEDING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG TOXICITY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0031861959     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401058     Document Type: Article

References (26)

1. Weiss M, Maslak P, Feldman E, Berman E, Bertino J, Gee T, Megherian L, Seiter K, Scheinberg D, Golde D. Cytarabine with high dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia (ALL) without the use of vincristine or prednisone. J Clin Oncol 1996; 14: 2480-2485.
2. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey F, Sobol R, Frankel S, Hooberman A, Westbrook C, Arthur D, Geolge S, Bloomfield C, Schiffer C. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia group B study 8811. Blood 1995; 85: 2025-2037.
3. Kantarjian HM, Walters RS, Keating MJ, Smith TL, O'Brien S, Estey EH, Huh Y, Spinola J, Dicke K, Barlogie B, Mcredie K, Freiriech E. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 1990; 8: 994-1004.
4. Linker CA, Levitt LJ, O'Donnell M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78: 2814-2822.
5. Schauer P, Arlin ZA, Mertelsmann R, Cirrincione C, Friedman A, Gee TS, Dowling M, Kempin S, Straus S, Koziner B, McKenzie S, Thaler H, Dufour P, Little C, Delloquila C, Ellis S, Clarkson B. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983; 1: 462-470.
6. Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki J, Metz E, Rivkin S, Grever M, Boldt D. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57-63.
7. Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 1993; 7: 139-160.
8. Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woloiver T, Royston I, Davey F, Flicksman A, Bloomfield C, Holland J. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991; 9: 2002-2015.
9. Willernze R, Peters WG, Colly LP. Short-term intensive treatment (VAAP) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma. Eur J Haematol 1988; 41: 489-495.
10. Fiere D, Extra JM, David B, Witz F, Vernand JP, Gastaut JA, Dauriac C, Pris J, Marty M. Treatment of 218 adult acute lymphoblastic leukemias. Semin Oncol 1987; 14: 64-66.
11. Clarkson B, Gaynor J, Little C, Berman E, Kempin S, Andreef M, Gulati S, Dunningham I, Gee T. Clinical trials in adults with acute lymphoblastic leukemia at Memorial Sloan-Kettering Cancer Center. Acute Lymphoblastic Leukemia. Alan R Liss: New York, 1990, pp 231-252.
12. Esterhay RJ, Wiernik PH, Grove WR, Markus SD, Wesley MN. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphoblastic leukemia. Blood 1982; 59: 334-345.
13. Terebolo HR, Anderson K,Wiernik PH, Cuttner J, Cooper RM, Faso L, Berenberg J. Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase. Am J Clin Oncol 1986; 5: 411-415.
14. RudnickSA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer 1979; 44: 1189-1193.
15. Capizzi RL, Poole M, Cooper MR, Richards F, Stuart JJ, Jackson DV, White D, Spurr C, Hopkins J, Muss H, Rudnick S, Wells R, Gabriel D, Ross D. Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 1984; 63: 694-700.
16. Amadori S, Papa G, Avvisati G, Fenu S, Monarca B, Petti MC, Pulsoni A, Mandelli F. Sequential combination high-dose Ara-C and asparaginase for the treatment of advanced acute leukemia and lymphoma. Leukemia Res 1984; 8: 729-735.
17. Wells RJ, Feusner J, Devney R, Woods W, Provisor A, Cairo M, Odom L, Nachman J, Jones G, Ettinger L, Capizzi R. Sequential high dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol 1985; 3: 998-1004.
18. Ishii E, Hara T, Ohkubo K, Matsuzaki A, Takeuchi T, Ueda K. Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin. Med Pediatr Oncol 1986; 14: 73-77.
19. Giona F, Testi A, Amadori S, Meloni G, Carotenuto M, Resegotti L, Colella R, Leoni P, Carella A, Grotto P, Miniero R, Mandelli F. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia. Ann Oncol 1990; 1: 51-55.
20. Berman E, Raymond V, Gee T, Kempin S, Gulati S, Andreef M, Kolitz J, Gabrilove J, Heller G, Young C, Clarkson B. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 1989; 16 (Suppl. 2): 3-34.
21. Hiddemann W, Buchner T, Heil G, Schumacher K, Diedrich H, Machmeyer G, Ho A, Planker M, Gerith-Stolzenburg S, Donhuijsen-Ant R, Lengfelder E, Hoelzer D. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990; 4: 637-640.
22. Lejeune C, Tubiana N, Gastaut JA, Maraninchi D, Richard B, Launay MC, Sainty D, Sebahoun G, Carcassonne Y. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Haematol 1990; 44: 240-243.
23. Kantarjian H, Walters R, Keating M, Estey EH, O'Brien S, Schachner J, McCredie K, Freireich E. Mitoxantrone and high dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 1990; 65: 5-8.
24. Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng Y, Baier M, Plezia P. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993; 11: 2002-2009.
25. National Cancer Institute, Division of Cancer Treatment. Common toxicity criteria. Bethesda.
26. Scheinberg D, Maslak P, Weiss M. Acute Leukemias. In: DeVita V, Hellman S, Rosenberg S (eds). Cancer: Principles and Practice of Oncology. Lippincott-Raven: New York, 1997, pp 2293-2321.